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Introduction: intravascular brachytherapy (IVBT) utilises the percutaneous insertion of a radioactive source to inhibit
myointimal hyperplasia in arteries treated by balloon angioplasty or stenting. A systematic review was performed of trials
of IVBT in patients with Peripheral Arterial Disease (PAD).
Methods: search strategy ± the reviewers searched Medline, Embase, the Cochrane Peripheral Vascular Diseases Group
trials register, DARE, CCT and NHS EED for clinical studies and trials of adjuvant IVBT in PAD. Two reviewers assessed
trial quality independently.
Results: fourteen clinical trials were identified by the search, representing five clinical studies (all allocated D for not
randomised) and one randomised controlled trial (allocated A). The randomised trial showed a benefit for IVBT compared
with placebo (OR 0.35, 95% CI 0.24±0.53). In the non-randomised studies, 12 month cumulative patency rates ranged from
60±87%. There were few technical complications. In the only report involving IVBT and routine concurrent stent insertion
acute thrombosis occurred in 7 (21%) of patients.
Conclusion: early reports have confirmed the safety and technical feasibility of IVBT. However, follow-up is too short at
present to assess the durability and long-term complications of this new therapeutic option.
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Introduction
Eur J Vasc Endovasc Surg 24, 377±382 (2002)
doi:10.1053/ejvs.2002.1742, available online at http://www.idealibrary.com onRestenosis following successful percutaneous trans-
luminal angioplasty (PTA) is the major cause of angio-
plasty failure in the medium-term.1±4 Restenosis may
be due to a number of processes: immediate elastic
recoil of the vessel, myointimal hyperplasia and late
vascular remodelling and progression of atheroscler-
osis.5±7 Superadded acute thrombosis can then lead to
complete occlusion of a restenosed vessel. Myointimal
hyperplasia is due to the excessive migration and
proliferation of vascular smooth muscle cells (SMCs),
leading to luminal narrowing and a restriction to
blood flow.8 The stimulus for this cellular migration
is unclear and therapeutic approaches are eagerly
sought to modulate this process as current 5-yearPlease address all correspondence to: G. Stansby, Department of
Surgery, University of Newcastle Upon Tyne, Framlington Place,
Newcastle Upon Tyne, NE2 4HH, U.K.
1078±5884/02/050377 06 $35.00/0 # 2002 Elsevier Science Ltd. Allpatency rates for iliac and femoropopliteal angio-
plasty are only 54±68% and 38±58% respectively.9±11
Although the concept of using localised radiation
to inhibit the proliferation of tumour cells is well
established, its use to inhibit SMC proliferation in
myointimal hyperplasia has only been explored in the
last 10±15 years. Intravascular brachytherapy (IVBT)
is based on the concept that proliferating SMCs are
more sensitive to the effects of lower doses of radi-
ation than non-proliferating cells.12 In vitro studies of
the effect of radiation on cells in culture have shown
that cells responded by the process of apoptosis
(programmed cell death) rather than necrosis, with
decreased proliferation of SMCs and fibroblasts and
a decrease in the synthesis of collagen.13 Furthermore,
it has been demonstrated that IVBT effectively mod-
ulates chronic vascular remodelling through its action
on adventitial cells.14 In this article we have aimed to
systematically review current data on the clinical use
of IVBT in peripheral arterial disease (PAD).rights reserved.
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Search strategy
Our search strategy attempted to locate all reports
of clinical series or trials of IVBT in PAD using
a combination of Medical sub-headings and free text
searches. Terms searched for included `` intravascular
brachytherapy'', `` intravascular radiotherapy'', `` intra-
vascular irradiation'', `` intravascular radiation'',
`` endovascular brachytherapy'', `` endovascular radio-
therapy'', `` endovascular irradiation'', `` endovascular
radiation'' with `` femoral'', `` popliteal'', `` femoropopli-
teal'', `` peripheral'', `` infrainguinal'', and `` lower limb''.
The following databases were searched:
1. MEDLINE from Jan. 1966±Jan. 2002;
2. EMBASE from 1980±Jan 2002;
3. The Cochrane Register of Clinical Controlled Trials
(CCTR) and Systematic Reviews (CDSR);
4. The Database of Abstracts of Reviews (DARE),
NHS Economic Evaluation Database (EED), Health
Technology Assessment Database (HTA) and Inter-
national Society of Technology Assessment in
Health Care (ISTAHC);
5. The Current Controlled Trials database (CCT);
6. Proceedings from the following vascular surgical
society meetings: Vascular Surgical Society of
Great Britain and Ireland, European Vascular Sur-
gical Society, North American Society of Vascular
Surgery.
The quality of the relevant studies retrieved was
assessed independently by two assessors (MH, KO)
using the checklist provided by the Cochrane Periph-
eral Vascular Diseases Collaborative Review Group,
with emphasis on concealment of randomisation.
Each reviewer gave trials an allocation score of ATable 1. Clinical studies of adjuvant IVBT in PAD.
Study group Year Type of study Lesions treated
Liermann15±20 1998 Non randomised In-stent recurrent SFA
stenosses occlusi
Minar21 1998 Non randomised Recurrent SFA
stenosses occlusi
Pichler23,24 1999 Non randomised De novo and recurre
PA stenossesocc
Wolfram28 2001 Non randomised De novo and recurre
stenosses occlusi
Waksman27 2001 Non randomised De novo SFA
stenosses occlusi
Vienna-222,25,29 2000 Randomised
controlled trial
De novo and recurre
stenosses occlusi
SFA superficial femoral artery, GyGray.
Eur J Vasc Endovasc Surg Vol 24, November 2002(appropriately randomised), B (method of randomisa-
tion unclear), C (inappropriately randomised) or D
(not randomised) and discrepancies between
reviewers was discussed with JS and GS and a con-
sensus reached.
Outcome measures
As well as details of technique used and type of
patients and lesions included, we attempted to extract
data on initial technical success or procedural compli-
cations, 6 and 12 month cumulative patency rates,
need for reintervention, limb loss and the use of adju-
vant antiplatelet or anticoagulant therapy.
Results
Characteristics of studies identified (Table 1)
Fourteen studies were identified after searching the
databases.15±28 After inspection it was clear that these
represented five non-randomised clinical studies with
no control group (allocated C) and ane randomised
controlled trial (allocated A) (Table 1). The difference
between the number of publications found and
studies involved was due to the fact that sequen-
tial updates were published by three of the groups
(Table 2).15±20,22±26 All of the studies used an iridium-
192 (192Ir) catheter-based afterloader system, using
doses of 12±14 Gray at the luminal surface. A total of
142 patients were treated in the uncontrolled studies
and 113 patients were entered into the controlled
study with 57 receiving angioplasty and IVBT and 56
patients angioplasty alone. Some studies enrolled
claudicants alone,27 others a mixture of claudicantsLesion
length
(cm)
Catheter Radioactive
source
Dose at
vessel
lumen (Gy)
ons
44 Non-centered 192Ir 12
ons
45 Non-centered 192Ir 12
nt SFA or
lusions
44 Non-centered 192Ir 14
nt SFA
ons
Any Centered 192Ir 14
ons
45±15 Centered 192Ir 14
nt SFA
ons
45 Non-centered 192Ir 12
IVBT and PAD 379and patients with critical ischaemia.20±23,28 The detail
given in some reports was unfortunately not sufficient
to identify the precise numbers of each. All of the
studies enrolled patients undergoing angioplasty for
superficial femoral artery stenoses. However, the pre-
cise type of lesions treated varied between studies
from those54 cm in length to up to lesions 5±15 cm
in length and all studies included both stenoses and
occlusions. In five of the six studies recurrent lesions
were also included.15±26,28
Results of IVBT (Table 2)
Initial technical success and complications
Technical success rates were high, with only one
study, which used a centering catheter, reporting tech-
nical problems ± in three patients the catheter kinked
and therefore the afterloader was not deployed.27
Wolfram's group who also used a centering catheter
reported no such procedural problems.28 In the
Vienna-2 trial three patients had immediate recur-
rences (within 24 h of procedure) and two patients
(one in each group) developed pseudoaneuryms at
the puncture site, which were successfully treated
with ultrasound guided compression. There were
also two groin haematomas and `` moderate ectasia''
of the treated segment of the vessel in six patients (one
in the PTA group, five in the PTA IVBT group).22
Late complications occurred in one study, whichTable 2. Results of clinical studies of adjuvant IVBT in PAD.
Study Number of
patients
treated
Procedure Antiplatelet/
anticoagulant
therapy
Liermann15±20 40 PTA IVBT Heparin 72 h
Warfarin 6 m
Minar21 10 PTA IVBT Heparin 72 h
Alprostadil 72
Aspirin 100 mg
Pichler23,24 24 PTA IVBT
 stent
Heparin 5000 IU
pre (long-term
not stated)
Wolfram28 33 PTA stent
insertion IVBT
Heparin 24 h
Clopidogrel 75
1 m Aspirin 10
Waksman27 35 PTA IVBT Heparin 5000 IU
pre Aspirin 325
Vienna-222,25,29 57 IVBT PTA IVBT Heparin 24 h
Aspirin 100 mg
56 control
 Started 2 weeks prior to procedure, continued indefinitely.
yContinued indefinitely.
z Specific patient details were not available, however an overall 82.5 preported an aneurysm at the treatment site at
6 months follow up, but further details were not
given.27 Recurrent stenosis at the edge of the treated
area was seen in two patients, one of whom under-
went IVBT with concurrent stent insertion and the
other had PTA IVBT alone.27,28 Acute thrombotic
occlusion occurred in one patient at 3 months in a
patient with in-stent restenosis treated with
PTA IVBT.17 However in the only trial that involved
concurrent stent insertion, seven patients (21%) pre-
sented with acute thrombotic occlusions at 3±
6 months (six of whom were successfully treated
with thrombolysis). All but one of the studies reported
the use of adjuvant antithrombotic or antiplatelet
agents (Table 2).
Patency (Table 2)
In the only randomised controlled trial (Vienna-2 trial)
117 patients were randomised to IVBT with 12 Gy
from an 192Ir afterloader, after successful PTA.22,25
Four patients were immediately excluded from the
trial, three due to acute thrombosis within 24 h of the
procedure and one patient refused IVBT after random-
isation. Follow-up data was available for 107 patients
at 6-months (54 in the PTA alone vs 53 in the
PTA IVBT). At 6-month follow up 25 patients pre-
sented with restenosis and four patients with occlu-
sions (54% failure rate) in the PTA alone group,
whilst there were 15 restenoses and no occlusions
(28% failure rate) in the PTA IVBT group.6 month
patency
%
12 month
patency
%
Reinterventions Limb loss
Data not
available z
Data not
available z
1 thrombolysis
2 PTA
Data not
available
h
80 60 4 PTA None
therapy
79 60 1 PTA relVBT
7 bypass
None
mg
0 mg y
70 Data not
available
7 thrombolysis
3 not started
Data not
available
mg y
83 87 2 PTA
1 bypass
1 not started
None
y
72 64 14 PTA None
46 35 20 PTA
2 bypass
atency rate was reported for a follow up of 4±90 months.
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380 M. Hansrani et al.An analysis of overall recurrence rates favoured
IVBT with an OR 0.35 (95% CI 0.24±0.53). Sub-group
analysis was performed of risk factors within this
group of patients and determined that the odd ratios
for restenosis post therapy were 0.46 (0.21±1.02) and
for complete occlusion were 0.10 (0.01±2.00). The
benefit of IVBT was not significant in restenotic
lesions which had undergone previous PTA [OR 0.32
(0.10±1.01)], de novo lesions [OR 0.42 (0.14±1.23)],
stenotic lesions [OR 0.61 (0.21±1.78)] or PTA treatment
length of 510 cm [OR 0.64 (0.13±3.25)], but demon-
strated significant benefit in patients who presented
with occlusive lesions [OR 0.19 (0.06±0.62)] or PTA
treatment lengths of 410 cm [OR 0.24 (0.09±0.62)].
Such comparative analysis was not possible for
the remaining five uncontrolled studies, including a
total of 142 patients. In four of these studies 6
month patency rates were reported and ranged from
70±83%.20,21,23,24,27,28 In three studies 12-month patency
rates were reported and ranged from 60±87%
(Table 2).17,19,21,24,27
Discussion
IVBT is at a relatively early stage of development in
the peripheral circulation with only five published
non-randomised series and one published rando-
mised trial to date. These early reports seem promis-
ing. The only randomised trial has shown a significant
benefit, with patency rates in the other studies com-
paring favourably to those in the literature for angio-
plasty alone. In addition, it should be noted that the
majority of the patients treated with IVBT in these
studies had restenotic lesions or long lesions. How-
ever, these results must be viewed with caution due
to the relatively small number of patients reported to
date, the inclusion of various types of lesion and the
relatively short follow up involved. All these studies
have used similar techniques, which have largely been
transferred from those used in the coronary circulation,
and technical complications appear to be infrequent.
Usually the source is delivered by an afterloader sys-
tem: after dummy wire insertion to ensure safe pas-
sage of the source, an `` unloaded'' tube is placed at the
target site and subsequently loaded with the radio-
active source (hence `` afterloader''). Computer con-
trolled remote afterloaders have now been developed
that insert the shielded radioactive source into the
unloaded tube, transfer it to the predetermined site
for a calculated time and then retract the source back
into its shielded container, thereby reducing operator
exposure to almost zero. Other technical advancesEur J Vasc Endovasc Surg Vol 24, November 2002such as the use of radioactive stents have not yet
been evaluation in the peripheral circulation.29±33
Leirmann et al. published the first human trial of
IVBT in 1994 using 12 Gy, the standard therapeutic
dosage used for the treatment of keloids, and the
studies in PAD have all used a similar dose.18,34 Clearly
it is sensible to use doses, which are known to be safe.
However, data from animal studies and trials in human
coronary vessels would suggest that this may repre-
sent a sub-optimal dose and the American Association
of Physics in Medicine (AAPM) in their Task Group
No. 60 recommend a dose of 15±30 Gy for preventing
clinical restenosis.35 Consequent to this, in the Vienna-
3 trial patients have been treated with 18 Gy delivered
by a centering catheter (personal communication from
Dr Pokrajac, Vienna, Austria). However, higher doses,
whilst more effective at preventing restenosis, may
also increase the risk of some complications. It has
been demonstrated that re-endothelialisation in radio-
active stents was delayed in a dose dependant manner
and at higher doses endocoronary irradiation is asso-
ciated with an increase in the number of thrombi and a
significant increase in platelet recruitment.36±39 Fur-
thermore, early trials of coronary IVBT revealed a
worryingly high incidence of late thrombosis, which
was significantly higher in patients who underwent
simultaneous stent insertion.40±43 The FDA recently
reviewed data from several coronary trials in relation
to this complication44 and recommended maintenance
of antiplatelet therapy for a minimum of 6 months
after IVBT and for one year if a new stent was simul-
taneously implanted. In all but one of the published
studies in PAD, patients were covered with heparin
peri-procedure and continued with either 6 months of
anticoagulation or long term aspirin therapy. How-
ever, there was still a high incidence of acute throm-
botic occlusion (21%) in the only trial in which IVBT
was combined with routine stent insertion, although
these were successfully treated with thrombolysis in
the majority of cases.28
If IVBT is to be introduced into routine practice,
then its practicality will be as important as its effect-
iveness. At present IVBT usually requires transfer of
the patient to a radiotherapy suite, which may add
30±45 min to the procedure, although the actual irra-
diation element requires only 200±656 s.22,27 In the
future, purpose-built suites may effectively remove
any difference in time between IVBT and conventional
angioplasty. However, these are likely to be costly. In
addition the costs of the radioactive material, special
sterilisation procedures, source shielding for transport
and storage, disposal costs, lead/glass goggles,
thyroid shields, lead aprons and lead (g sources) or
Perspex/plastic (b sources) shields, the computers
IVBT and PAD 381and computer software may make the technique pro-
hibitively expensive for most units.
The delivery of IVBT via a radioactive stent is an
attractive theoretical concept not yet tried in the peri-
pheral arteries. However, the initial enthusiasm for
radioactive coronary artery stenting has, to an extent,
been diminished as results from trials emerge.29
Though IVBT appears to be initially successful in redu-
cing in-stent restenosis in a dose-dependant manner,
this benefit was offset by the occurrence of increased
luminal narrowing at the edges of the stent, known
as the `` edge effect''.45 This is due to the stimulation of
SMC proliferation and loss of the positive remodelling
effect induced by the low doses of radiation found at
the edges of a radioactive stent. Developments in bal-
loon and stent technology to overcome this IVBT-
induced restenosis are currently being evaluated,
however, these problems have led many researchers
to suggest that radioactive stents currently have no
place in coronary clinical practice.30,31,33 As a result
such radioactive stents have not been used in periph-
eral arteries and seem unlikley to be used unless more
encouraging data emerges in the future, especially if
stents themselves seem to increase the rate of acute
thrombotic occlusion.
Another potential problem relates to aneurysm for-
mation at the treatment site. Fibrosis of irradiated
vessels may lead to a dose related weakening of the
vessel wall and this may lead to late aneurysm forma-
tion.46,47 In the first published series of coronary IVBT,
four aneurysms occurred by 3-year follow up.48
Asymmetric centering of the source can lead to focal
areas of the wall receiving a much higher dose of
radiation in excess of 50 Gy.35 Reduction of this
potential hazard with the increased use of centering
and liquid filled balloon catheters seems sensible but
centering catheters have been used in only two of the
studies in PAD to date. The only aneurysm reported in
the PAD studies occurred subsequent to a dissection
at the time of the initial procedure.27 Whether the
ectasia found in the Vienna-2 trial will progress to
aneurysm formation will only emerge when longer
term follow up is available. No evidence of other
local problems such as nerve damage or local malig-
nancy has been observed over the relatively short
follow up period. Several of the studies have, how-
ever, only enrolled elderly patients due to concerns
regarding the potential development of malignancy.49
Conclusions
The use of ionising radiation to reduce restenosis due
to myointimal hyperplasia following endovascularintervention is a promising innovative treatment
modality. However, many questions have yet to be
answered regarding the most effective method of
delivery, its long-term safety and issues regards
thrombosis and aneurysm formation after therapy
with IVBT. Initial trial results suggest that adjuvant
IVBT to long segment SFA disease may be more effect-
ive than existing treatments. Currently, however, the
technique is cumbersome and the safety requirements
are very demanding. On the basis of experience in
coronary IVBT and one report in PAD, concurrent
stent insertion cannot be recommended because of
the worrying incidence of acute thrombotic occlu-
sions. Further clinical trials and technological
advances will be needed before IVBT can be recom-
mended as a routine treatment modality in PAD. With
the current focus on the cost effective delivery of
health care provisions the issues regarding costs and
benefits of IVBT must be addressed if this treatment
is to become widely established. The results from
on-going clinical trials (Vienna-3, PARIS, Swiss and
VARA) are eagerly awaited.
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